Investigational Drug Information for Bemcentinib
✉ Email this page to a colleague
What is the drug development status for Bemcentinib?
Bemcentinib is an investigational drug.
There have been 10 clinical trials for Bemcentinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 26th 2017.
The most common disease conditions in clinical trials are Lung Neoplasms, Preleukemia, and Myelodysplastic Syndromes. The leading clinical trial sponsors are BerGenBio ASA, Merck Sharp & Dohme Corp., and BerGenBio AS.
There are thirteen US patents protecting this investigational drug and two hundred and thirty-five international patents.
Summary for Bemcentinib
US Patents | 13 |
International Patents | 235 |
US Patent Applications | 142 |
WIPO Patent Applications | 122 |
Japanese Patent Applications | 19 |
Clinical Trial Progress | Phase 2 (2017-07-26) |
Vendors | 60 |
Recent Clinical Trials for Bemcentinib
Title | Sponsor | Phase |
---|---|---|
A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer | BerGenBio ASA | Phase 1/Phase 2 |
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients | BerGenBio ASA | Phase 2 |
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery | BerGenBio ASA | Early Phase 1 |
Clinical Trial Summary for Bemcentinib
Top disease conditions for Bemcentinib
Top clinical trial sponsors for Bemcentinib
US Patents for Bemcentinib
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Bemcentinib | ⤷ Try a Trial | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Try a Trial |
Bemcentinib | ⤷ Try a Trial | Anti-Axl antagonistic antibodies | BERGEN TEKNOLOGIOVERFORING AS (Bergen, NO) BERGEBIO ASA (Bergen, NO) | ⤷ Try a Trial |
Bemcentinib | ⤷ Try a Trial | Methods of detecting Akt3 and administering Ax1 inhibitor | BERGENBIO ASA (Bergen, NO) | ⤷ Try a Trial |
Bemcentinib | ⤷ Try a Trial | Pharmaceutically active compounds | BerGenBio ASA (Bergen, NO) | ⤷ Try a Trial |
Bemcentinib | ⤷ Try a Trial | Combination therapy with an anti-axl antibody-drug conjugate | ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB) | ⤷ Try a Trial |
Bemcentinib | ⤷ Try a Trial | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bemcentinib
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Bemcentinib | Australia | AU2016322552 | 2035-09-14 | ⤷ Try a Trial |
Bemcentinib | Canada | CA2998469 | 2035-09-14 | ⤷ Try a Trial |
Bemcentinib | China | CN108349985 | 2035-09-14 | ⤷ Try a Trial |
Bemcentinib | China | CN114230571 | 2035-09-14 | ⤷ Try a Trial |
Bemcentinib | European Patent Office | EP3350183 | 2035-09-14 | ⤷ Try a Trial |
Bemcentinib | Hong Kong | HK1261923 | 2035-09-14 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |